Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial. (linkinghub.elsevier.com)

Authors: Zeng L … Zhang Y Journal: Cell Reports Medicine Published: 2026-07-22 DOI: https://doi.org/10.1016/j.xcrm.2026.102931